Complete FDA and NHTSA recall records dated in February 2023.
These records include useful source details for the selected month.
Due to a software bug, under certain conditions, pressure cannot be built up resulting in no ventilation. If gas delivery is stopped, a sustained decrease in delivered O2 concentration may…
Due to a software bug, under certain conditions, pressure cannot be built up resulting in no ventilation. If gas delivery is stopped, a sustained decrease in delivered O2 concentration may…
Weld protrusion/physical gap between the housing and phaco pack cover, may exceed design specification, which could lead to priming cycle failure and/or suboptimal vacuum delivered to the…
Due to a software bug, under certain conditions, pressure cannot be built up resulting in no ventilation. If gas delivery is stopped, a sustained decrease in delivered O2 concentration may…
Potential for pilot balloon non-inflation or cuff non-deflation.
Leakage of the original specimen from the plastic microfluidic cartridge (PIE), possibility that laboratory personnel may be exposed to aerosolized specimen containing SARS-CoV-2
There is an orogastric (OG) tube size discrepancy between the labeling in the IFU and the printed text on the device. If the clinician is unable to pass a gastric catheter through one of…
Product may contain undeclared almonds.
The recalled product contains undeclared milk, soy, peanuts, tree nuts (almonds, walnuts, pecans, cashews), and sulfites
Parsley imported from Mexico was found to be contaminated with Salmonella
Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back
Short Fill
CGMP Deviations: potential for trace amounts of product carryover.
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Presence of Particulate Matter: Glass particulate matter detected in injectable.
Discoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective product
CGMP Deviations: potential for trace amounts of product carryover.
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Use this page to compare the recalls reported during the month, then open an individual record for the exact reason, classification, company, remedy or distribution information available from the official source. Monthly counts are descriptive, not a safety rating.
